Requests · The University of Texas at Arlington

Institute of Biomanufacturing and Precision Medicine for North Texas

Priority 1 · one of 3 items in the The University of Texas at Arlington's request for 2028-29 · The item begins on page 86 of the request

This is a request, not an appropriation.

What is asked

20282029Two years
All funds$9,000,000$9,000,000$18,000,000
Of which general revenue and general revenue-dedicated $9,000,000$9,000,000$18,000,000
Positions (full-time equivalents) 50.050.0

How it would be financed

Method of financing, as the request prints it20282029
1 General Revenue Fund$9,000,000$9,000,000
Total, as the request prints it$9,000,000$9,000,000

Where it would land

The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.

Strategy Asked 2028Asked 2029Positions Appropriated 2026Appropriated 2027
03-02-02 Institute of Biomanufacturing and Precision Medicine for North Texas $9,000,000$9,000,00050.0No strategy matched in the current budget

A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.

After 2029

The agency's estimate203020312032Three years
All funds$9,000,000$9,000,000$9,000,000$27,000,000

In the agency's words: Sustaining the work of the Institute will require continued funding of the program at the same level of support as the 2028-29 request.

The agency's justification

UTA requests $18.0 million for the 2028-29 biennium for IMPRINT, the Institute of Biomanufacturing and Precision Medicine for North Texas. Building upon the partial funding received from the Legislature beginning in the 2024-25 biennium, IMPRINT advances Texas’ health and economic priorities by accelerating biomedical discovery into therapeutic development, scalable biomanufacturing, and workforce preparation.

The Institute of Biomanufacturing and Precision Medicine for North Texas (IMPRINT) develops and operates the infrastructure, partnerships, and translational capabilities needed to move biomedical discoveries from academic research to clinical and commercial impact. The institute addresses a critical gap in the life sciences ecosystem: the distance between promising scientific discoveries and the commercially viable therapeutic candidates, manufacturing capabilities, and companies required to deliver those innovations to patients. Through strategic collaborations with academic institutions, healthcare systems, and industry leaders across Texas, IMPRINT supports the full pathway from discovery and development through manufacturing , regulatory readiness, and market translation.

IMPRINT is helping establish a unique Texas capability: an integrated translational-to-commercialization ecosystem for therapeutics and precision medicine that spans discovery, development, manufacturing, and commercialization. This infrastructure generates venture-backable assets, enables startup formation, strengthens innovation hubs such as Pegasus Park, expands biotechnology capacity across North Texas, and creates shared resources that benefit the broader life sciences ecosystem. By connecting innovation with commercialization, IMPRINT advances patient care while strengthening Texas' competitiveness in biotechnology, advanced manufacturing, and economic development.

External and internal factors

For additional information, see Schedule 9, Non-Formula Support

As marked in the request